
Simulations Plus (SLP) Stock Forecast & Price Target
Simulations Plus (SLP) Analyst Ratings
Bulls say
Simulations Plus, Inc. reported a total revenue of $20.4 million for F3Q, aligning closely with the consensus estimate of $20.3 million and exceeding its own guidance range, which signals strong operational performance. The recent acquisition of Proficiency presents opportunities for organic revenue growth to potentially re-accelerate toward high-single digits in FY26, which is promising given the company's past challenges with customer concentration and biotech exposure. The anticipated revenue mix of 55-60% from software and 40-45% from services underscores the company's solid position within the pharmaceutical research sector, further supporting a positive outlook.
Bears say
Simulations Plus faces significant challenges due to its customer concentration and exposure to the biotech sector, which is currently experiencing weaker demand, leading to a negative near-to-middle-term outlook without anticipated recovery. In the most recent financial quarter, the company's software revenue of $12.6 million fell short of the $13.6 million consensus, despite service revenue exceeding expectations. Additionally, operating expenses surpassed projections, with SG&A expenses at $8.8 million above consensus and R&D costs undershooting expectations, which complicates the potential for financial recovery and growth.
This aggregate rating is based on analysts' research of Simulations Plus and is not a guaranteed prediction by Public.com or investment advice.
Simulations Plus (SLP) Analyst Forecast & Price Prediction
Start investing in Simulations Plus (SLP)
Order type
Buy in
Order amount
Est. shares
0 shares